tiprankstipranks
Trending News
More News >
Noevir Holdings Co., Ltd. (JP:4928)
:4928
Japanese Market

Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Noevir Holdings Co., Ltd.

(4928)

Rating:74Outperform
Price Target:
¥4,798.00
▲(10.55%Upside)
Noevir Holdings Co., Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet. The valuation is appealing, driven by a reasonable P/E ratio and a high dividend yield. Technical indicators show mixed signals, with potential short-term weakness but also signs of being oversold, which could offer buying opportunities. The absence of recent earnings call data or notable corporate events results in these components not influencing the score.

Noevir Holdings Co., Ltd. (4928) vs. iShares MSCI Japan ETF (EWJ)

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company DescriptionNoevir Holdings Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of cosmetics, pharmaceuticals, and health-food products. The company operates through various segments, including Cosmetics, Pharmaceuticals, and Others. Its core products include skincare, makeup, and nutritional supplements, designed to enhance beauty and wellness. Noevir is known for its high-quality, innovative formulas and its commitment to research and development, leveraging both traditional and modern scientific approaches to create effective and safe products.
How the Company Makes MoneyNoevir Holdings Co., Ltd. generates revenue through its diversified product lines across several key segments. The primary revenue stream comes from the Cosmetics segment, which includes the sale of skincare, makeup, and beauty products. This segment benefits from a well-established distribution network, including direct sales channels and retail partnerships. Additionally, Noevir earns income from its Pharmaceuticals segment, which includes the development and sale of health-related products and over-the-counter medications. The company also capitalizes on its Health Food segment, offering nutritional and dietary supplements. Moreover, Noevir's investments in research and development contribute to its competitive edge, ensuring a steady pipeline of new and innovative products. Strategic partnerships and collaborations also play a role in expanding its market reach and enhancing its brand presence globally.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary
Noevir Holdings Co., Ltd. presents a strong financial profile with consistent profitability and a robust balance sheet. Revenue and profit margins are solid, while leverage remains low, indicating financial prudence. However, cash flow generation shows some decline, which, although still sufficient, could affect future investment capacity.
Income Statement
85
Very Positive
The income statement reveals a positive trajectory with stable revenue growth, evidenced by a 2.3% increase in revenue from the previous year. The gross profit margin remains strong at 67.06% for TTM, and the net profit margin is healthy at 12.48%. EBIT and EBITDA margins indicate efficient operations with EBIT at 17.08% and EBITDA at 19.04%. While the company shows consistent profitability, slight fluctuations in EBIT suggest some operational cost pressures.
Balance Sheet
82
Very Positive
The balance sheet shows a robust financial position with a low debt-to-equity ratio of 0.02, reflecting minimal leverage. The equity ratio is strong at 66.45%, indicating substantial equity financing. Return on equity stands at 16.59%, demonstrating effective use of equity to generate profits. Overall, the balance sheet highlights financial stability, though the slight decrease in stockholders' equity warrants monitoring.
Cash Flow
78
Positive
Cash flow analysis shows a decrease in operating cash flow year-over-year, with a TTM free cash flow growth rate of -37.36%. The operating cash flow to net income ratio is 0.86, while the free cash flow to net income ratio is 0.63, suggesting adequate conversion of net income into free cash flow. Despite some decline in free cash flow, the company maintains sufficient liquidity to support its operations.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue64.23B63.82B62.55B61.14B51.27B51.84B
Gross Profit43.09B43.16B42.56B42.09B33.03B33.08B
EBITDA12.23B12.63B12.24B11.57B10.05B9.76B
Net Income8.01B7.97B7.67B7.59B6.38B5.62B
Balance Sheet
Total Assets72.70B76.47B77.25B76.78B80.45B80.05B
Cash, Cash Equivalents and Short-Term Investments23.80B29.22B28.88B29.75B31.10B29.46B
Total Debt785.00M828.00M914.00M1.00B1.11B1.22B
Total Liabilities23.84B22.57B24.04B24.40B28.22B27.81B
Stockholders Equity48.32B53.48B52.79B52.05B51.93B51.98B
Cash Flow
Free Cash Flow5.08B8.11B6.57B5.23B8.63B5.67B
Operating Cash Flow6.91B9.12B7.62B5.84B9.06B7.31B
Investing Cash Flow-2.40B1.52B-3.54B-255.00M-416.00M-1.61B
Financing Cash Flow-7.87B-7.71B-7.49B-7.38B-7.18B-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4340.00
Price Trends
50DMA
4253.00
Positive
100DMA
4225.70
Positive
200DMA
4586.19
Negative
Market Momentum
MACD
19.12
Negative
RSI
61.30
Neutral
STOCH
75.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Positive. The current price of 4340 is above the 20-day moving average (MA) of 4286.50, above the 50-day MA of 4253.00, and below the 200-day MA of 4586.19, indicating a neutral trend. The MACD of 19.12 indicates Negative momentum. The RSI at 61.30 is Neutral, neither overbought nor oversold. The STOCH value of 75.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥148.24B18.50
5.18%1.51%5.48%
68
Neutral
¥197.78B21.088.29%2.34%4.99%3.05%
66
Neutral
$279.63B37.444.49%3.32%-0.74%-25.66%
64
Neutral
$336.37B57.422.08%2.37%4.63%-60.17%
60
Neutral
¥1.05T496.62
1.52%-1.33%-139.30%
60
Neutral
$390.25B36.515.17%1.67%-8.36%-38.35%
59
Neutral
$398.82B18.747.58%2.04%2.30%33.87%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4928
Noevir Holdings Co., Ltd.
4,340.00
-1,136.51
-20.75%
JP:4911
Shiseido Company,Limited
2,627.00
-1,982.89
-43.01%
JP:4967
Kobayashi Pharmaceutical Co
5,262.00
-28.38
-0.54%
JP:4927
Pola Orbis Holdings
1,264.00
-26.29
-2.04%
JP:4922
Kose
5,896.00
-3,931.26
-40.00%
JP:4912
Lion
1,469.50
218.20
17.44%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Mixed Financial Results for First Half of Fiscal Year 2025
May 8, 2025

Noevir Holdings reported its consolidated financial results for the first six months of the fiscal year ending September 30, 2025, showing a slight increase in net sales by 1.3% compared to the previous year. However, the company faced a decline in operating and ordinary income, with operating income dropping by 7.3% and ordinary income by 3.5%. Despite these challenges, net income attributable to owners of the parent increased by 1.7%. The equity ratio also decreased from 69.9% to 66.5%, indicating changes in the company’s financial position. The company maintained its dividend forecast, signaling stability in shareholder returns.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025